- Company to present Vision 20/20 and new data supporting early stage product candidates -
COPENHAGEN, Denmark, Aug. 15, 2016 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biopharmaceutical company that applies its innovative TransCon technology to address significant unmet medical needs, today announced that the company will host an R&D Update for the investment community on Friday, September 30, 2016 in New York City.
The event will feature an overview of Ascendis' Vision 20/20 to build a leading, commercially-integrated, rare disease company addressing significant unmet medical needs.
Presentations by outside experts and Ascendis senior management will highlight the market opportunity, product profiles, data and development plans for TransCon Growth Hormone, as well as for two new rare disease endocrinology product candidates.
R&D Update Event Information
Friday, September 30, 2016
8:30 a.m. - 11:30 a.m. ET (Registration to begin at 8:00 a.m. ET)
New York, NY
If you are a member of the investment community and would like to attend, please send an email to firstname.lastname@example.org to receive additional information.
A live webcast of the R&D Update will be made available on the Investors & News section of the Ascendis Pharma website at www.ascendispharma.com. More information about how to access the webcast will be available closer to the event.
About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative TransCon technology to develop an internal pipeline of therapeutics to address unmet medical needs in rare disease indications carrying substantial commercial potential. The Ascendis Pharma internal pipeline consists of existing parent drugs with known pharmacology, and features TransCon Growth Hormone, a wholly-owned program that has completed Phase 2 studies in adults and children with Growth Hormone Deficiency. The global Phase 3 heiGHt Trial was initiated in August 2016.
Additionally, Ascendis Pharma has formed collaborations with Sanofi in diabetes and Genentech in the field of ophthalmology, both of which are focused on developing leading products in large markets of strategic importance to these partners.
The TransCon technology combines the benefits of prodrug and sustained release technologies, and is the key driver of Ascendis Pharma's mission to develop a pipeline of therapeutics with best-in-class profiles. The TransCon technology can be applied to a broad range of drug therapies, including proteins, peptides and small molecules, to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. For more information, please visit www.ascendispharma.com.
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) our product pipeline, (ii) our plan to become a leading, commercially-integrated, rare disease company, (iii) the market opportunity, product profiles, data and development plans for TransCon Growth Hormone , (iv) the market opportunity, product profiles, data and development plans for any potential new rare disease endocrinology product candidates, and (v) the application of our TransCon technology to the creation of product candidates to address significant unmet medical needs in rare disease indications carrying substantial commercial potential. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make, including the following: unforeseen safety or efficacy results in our lead development program TransCon Growth Hormone or other development programs; unforeseen expenses related to the development of TransCon Growth Hormone or other development programs, general and administrative expenses, other research and development expenses and our business generally; delays in the development of TransCon Growth Hormone related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; and our ability to obtain additional funding, if needed, to support our business activities. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to our business in general, see our current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F for the year ended December 31, 2015, which we filed with the SEC on April 15, 2016. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments we may enter into or make. We do not assume any obligation to update any forward-looking statements, except as required by law.
Scott T. Smith
Chief Financial Officer
+1 (650) 352-8389
+1 (415) 513-1284
+1 (650) 739-9952
SOURCE Ascendis Pharma